Results 141 to 150 of about 2,138,197 (387)

Determination of B-cell clonality in Hodgkin’s lymphoma

Клиническая онкогематология, 2014
B-cell origin of Hodgkin’s lymphoma was demonstrated using microdissection and single cell PCR of Reed-Sternberg and Hodgkin cells (R. Kuppers et al., 1994).
Yu. V. Sidorova, N. V. Ryzhikova, S. Yu. Smirnova, E. E. Nikulina, B. V. Biderman, A. M. Kovrigina, T. N. Moiseeva, N. N. Sharkunov, A. B. Sudarikov   +8 more
doaj   +1 more source

Enhancing Magnetic Hyperthermia at the Cell Membrane by Anchoring 92R‐Functionalized Magnetic Nanoparticles to Low‐Endocytic CCR9 Surface Receptors

Advanced Healthcare Materials, EarlyView.
We present a strategy to enhance magnetic hyperthermia therapy by modulating nanoparticle–cell interactions. Antibody‐functionalized magnetic nanoparticles targeting the low‐internalizing CCR9 receptor enable spatially controlled membrane anchoring, reducing aggregation and maximizing heat generation under alternating magnetic fields.
David Egea‐Benavente, Isabel Corraliza‐Gorjón, Thomas S. van Zanten, María del Puerto Morales, Leonor Kremer, Domingo F. Barber   +5 more
wiley   +1 more source

Diffuse large B-cell lymphoma

Dermatology Online Journal, 2012
We present a 56-year-old man with a two-year history of erythematous nodules and plaques on the forehead, frontal aspect of the scalp, and left side of the neck. Histopathologic findings are compatible with a diagnosis of diffuse large B-cell lymphoma (DLBCL).
Mundi, Jyoti P, Leger, Marie, Terushkin, Vitaly, Fischer, Max, Patel, Rishi, Meehan, Shane, Latkowski, Jo-Ann   +6 more
openaire   +4 more sources

TRIM47 Regulates Energy Metabolism via Glycolytic Reprogramming to Drive Hepatocellular Carcinoma Progression and Represents an Efficient Therapeutic Target

Advanced Science, EarlyView.
This study identifies TRIM47 as a key driver of liver cancer progression by promoting glycolysis through ubiquitin‐mediated degradation of the gluconeogenic enzyme FBP1. TRIM47 enhances glucose uptake, lactate and ATP production, and tumor growth and metastasis.
Weijie Sun, Yihang Yuan, Qian Qiu, Kexuan Tan, Xutong Li, Haotian Li, Luyang Kang, Yuting Gu, Ziheng Zhang, Jiayu He, Jiali Li, Junjie Lin, Zihan Xie, Kexing Han, Jiabin Li, Yang Zhang, Ting Wu, Yufeng Gao   +17 more
wiley   +1 more source

Expression of interleukin 2 receptors on activated human B cells. [PDF]

, 1984
Using anti-Tac, a monoclonal anti-interleukin 2 (IL-2) receptor antibody, we have explored the possibility that certain activated B cells display receptors for IL-2.
Bongiovanni, KF, Depper, JM, Goldman, CK, Greene, WC, Korsmeyer, SJ, Leonard, WJ, Robb, RJ, Sharrow, SO, Waldmann, TA   +8 more
core  

Targeting the Bcl-2 Family in B Cell Lymphoma

Frontiers in Oncology, 2019
Although lymphoma is a very heterogeneous group of biologically complex malignancies, tumor cells across all B cell lymphoma subtypes share a set of underlying traits that promote the development and sustain malignant B cells.
Clare M. Adams, S. Clark-Garvey, P. Porcu, C. M. Eischen   +3 more
semanticscholar   +1 more source

FAPα+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD‐L1 and T Cell Senescence

Advanced Science, EarlyView.
Fibroblast activation protein alpha‐positive (FAPα+) macrophages, a distinct subset of multiple myeloma (MM)‐associated macrophages, drive immune evasion in MM through multi‐faceted mechanisms. FAPα physically interacts with vimentin (VIM) and triggers its phosphorylation at the S72 residue, which in turn induces PD‐L1 transcription. Additionally, FAPα
Huiyao Gu, Zhenfeng Dai, Xi Huang, Enfan Zhang, Xinyuan Dai, Haoguang Chen, Wen Cao, Jinna Zhang, Yifan Hou, Haimeng Yan, Yang Yang, Li Yang, Yi Li, Wenlong Lin, Zhen Cai, Jingsong He   +15 more
wiley   +1 more source

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

New England Journal of Medicine, 2002
B. Coiffier, É. Lepage, J. Brière, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, F. Reyes, P. Lederlin, C. Gisselbrecht   +12 more
semanticscholar   +2 more sources

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source

Strawberry Notch 1 Acts as a Transcriptional Regulator Driving Oncogenic Programs in Liver Carcinogenesis

Advanced Science, EarlyView.
This study reports that SBNO1 protein is upregulated in several cancer entities. SBNO1 protein interacts with the basal transcription factor TFIID via TAF4, enabling its recruitment to transcription start sites and the modulation of target gene expression.
Sarah Fritzsche, Raisatun Nisa Sugiyanto, Kira Gür, Alina Krumme, Maxime Le Marois, Angelika Fraas, Aslihan Inal, Mario Huerta, Vanessa Henriques, Eva Eiteneuer, Thomas Albrecht, Alphonse Charbel, Michael T. Dill, Carsten Sticht, Carolina De La Torre, Stefan Pusch, Arianeb Mehrabi, Kai Breuhahn, Junfang Ji, Peter Schirmacher, Benjamin Goeppert, Stephanie Roessler   +21 more
wiley   +1 more source